OncoTargets and Therapy | |
Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives | |
关键词: HER2; trastuzumab; gastric cancer; immunohistochemistry; in-situ hybridisation; | |
DOI : | |
来源: DOAJ |
【 摘 要 】
Michael Davidson, Naureen StarlingDepartment of Gastrointestinal Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, UKAbstract: The addition of trastuzumab to the treatment of a subset of patients with advanced gastric and gastroesophageal junction cancers showing HER2 positivity has been shown to confer clinical benefit; however, questions remain over the optimal methods for defining and selecting such patients. This review provides an overview of current standards for assessing HER2 positivity, the evolving treatment landscape for HER2-positive gastric and esophageal cancers and the challenges and potential future directions in optimal patient selection for HER2-targeted therapy.Keywords: HER2, trastuzumab, gastric cancer, immunohistochemistry, in situ hybridization
【 授权许可】
Unknown